Sixpex presents mazdutide in a single 3 ml vial, each milliliter carrying 10 mg of the peptide. The product arrives as a lyophilized powder requiring reconstitution before use, standard for peptide formulations of this class. Mazdutide is a dual GLP-1/glucagon receptor agonist peptide, distinct from single-target compounds such as semaglutide or the triple-agonist profile of retatrutide. This vial holds one discrete unit; no multi-pack option is included.

Sixpex Mazdutide at 10 mg Concentration

The 10 mg per ml concentration gives 30 mg total peptide content across the 3 ml volume. Sixpex, a USA-based company producing peptides since 2024, supplies this formulation with a certificate of analysis documenting batch purity and identity. The vial is sealed and labeled with batch number and reconstitution guidelines. Other mazdutide listings may present different volumes or multi-vial packs; this one offers a single 3 ml container.

Single Vial Pack and Peptide Form

The pack contains one vial only. Lyophilized peptides require bacteriostatic water or another suitable diluent, sold separately. Once mixed, the solution must be refrigerated and used within the stability window stated in the product insert. The vial's 3 ml capacity allows for flexible reconstitution volumes depending on target concentration per injection.